

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

506.40278X00 filed June 22, 2001

U.S. APPLICATION NO. (Unknown, see 37 CFR 1.5)

JUN 2 2001 869049

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/JP98/05857

24 December 2998 (24.12.98)

TITLE OF INVENTION PHARMACEUTICAL PREPARATIONS

APPLICANT(S) FOR DO/EO/US KATO, Yasuki; KUSANO, Hiroko; KAWAGUCHI, Yuji; and ITO, Kunio

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☒ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

International Publication No. WO00/38736-coversheet
 International Preliminary Examination Report
 International Search Report
 Credit Card Payment Form
 PCT Request Form

APPLICATION NO. (UNKNOWN) 37 CFR 1.492

09/869049

INTERNATIONAL APPLICATION NO.
PCT/JP98/05857ATTORNEY'S DOCKET NUMBER
506.40278X0021. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a) (2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =**CALCULATIONS PTO USE ONLY**

\$ 860.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	10 -20 =	0	x \$18.00	\$ 0.00
Independent claims	1 -3 =	0	x \$80.00	\$ 0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 270.00

TOTAL OF ABOVE CALCULATIONS =

\$ 1,130.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2.

\$ 0.00

SUBTOTAL =

\$ 1,130.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$ 0.00

TOTAL NATIONAL FEE =

\$ 1,130.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$ 40.00

TOTAL FEES ENCLOSED =

\$ 1,170.00

Amount to be
refunded: \$

charged: \$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 01-2135. A duplicate copy of this sheet is enclosed.
- d. ☒ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

William I. Solomon
Antonelli, Terry, Stout & Kraus, LLP
1300 North Seventeenth Street
Suite 1800
Arlington, VA 22209

SIGNATURE

William I. Solomon

NAME

28,565

REGISTRATION NUMBER

SPECIFICATION
PHARMACEUTICAL PREPARATIONS

Technical Field

5 The present invention relates to pharmaceutically useful preparations designed for altering the in vivo behavior of pharmaceutical compounds so as to efficiently secure their effects.

10 Background Art

Peptides and proteins have been widely utilized as pharmaceuticals. It is known to chemically modify pharmaceuticals such as peptides and proteins with polyethylene glycol, dextran, polyamino acids, albumin, inulin, etc. in order to prolong their action in vivo.

On the other hand, attempts have been made to develop targeting preparations of pharmaceuticals such as peptides and proteins. For example, it is reported that the modification of lysozyme and albumin [J. C. Rogers and S. Kornfeld, Biochem. Biophys. Res. Commun., 45, 622 (1971)] and glutaminase [G. Schemer et al., Biochem. Biophys. Acta, 538, 397 (1978)] with asialoglycoproteins is effective for targeting of these substances towards liver. It is also observed that the chemical modification of albumin [L. Fuime et al., FEBS Lett., 146, 42 (1982), L. Fuime et al., Biochem. Pharmacol., 35, 967 (1986)], L-asparaginase [J. W. Marsh et al., J. Biol. Chem., 252, 7678 (1977)] and ribonuclease [G. Wilson, J. Biol. Chem., 253, 2070 (1977)] with lactose enhances the accumulation of these substances at liver. Chemical modification techniques useful in such targeting include the carbodiimide method, the glutaraldehyde method, the SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate) method, the active ester method and the reduction method using sodium cyanoborohydride. The compounds prepared by chemically modifying pharmaceuticals such as peptides and proteins using these techniques are gradually decomposed in vivo to release

the pharmaceuticals, but they can not be expected to rapidly release the pharmaceuticals in response to changes in pH or the like.

It is known that the pH of interstitium is lowered to a level of 6.9 in cancer cells etc. and that administration of glucose lowers the pH of interstitium from 6.9 to 6.2 [H. Kahler and W. V. Robertson, *J. Natl. Cancer Inst.*, 3, 495 (1943), P. M. Gullino et al., *J. Natl. Cancer Inst.*, 34, 857 (1965)]. It is also known that inflamed parts have a pH in the acidic range, i.e. pH 6.5 [V. Menkin, *Biochemical Mechanism in Inflammation*, Thomas, Springfield, III, pp. 69-7 (1956)]. Further, it has been experimentally demonstrated that transient ischemia in rats lowers the pH of the affected part from 7.4 to 6.5 [N. Watanabe et al., *Biochem. Pharmacol.*, 38, 3477 (1989)]. Also known is a pH-sensitive drug delivery system (DDS) for superoxide dismutase (SOD) using a styrene-maleic acid copolymer (SM) [Biochemistry, 28, 6619 (1989), *Biochem. Pharmacol.*, 38, 3477 (1989)]. In this DDS, superoxide dismutase covalently bound to the styrene-maleic acid copolymer (SM-SOD) noncovalently binds to the warfarin site on albumin in blood at pH around neutrality. As the pH is lowered, SM is protonated and the albumin-binding ability thereof is decreased to cause release of SM-SOD.

It is also known that epidermal growth factor (EGF) receptor is excessively expressed at squamous cell carcinoma [S. Ogawa et al., *Jpn. J. Cancer Res.*, 79, 1201 (1988)], and based on this fact, targeting therapy using a carcinostatic agent together with anti-EGF receptor antibody has been attempted [E. A. Pirak et al., *Proc. Natl. Acad. Sci. USA*, 86, 3778 (1989)]. Tsuchiya et al. have found that by binding EGF to the surface of liposome, the liposome is incorporated into cancer cells via the EGF receptor [S. Tsuchiya et al., *Drug Delivery System*, 4, 193 (1989)]. However, the EGF receptor is expressed also in normal cells, and it is difficult to specifically target diseased parts.

Disclosure of the Invention

5 An object of the present invention is to provide a pharmaceutical preparation (a pH responsive pharmaceutical preparation) which is capable of rapidly releasing a compound having a free amino group such as an amino acid derivative, a peptide, a protein or an enzyme in response to changes in pH at focuses by reacting the compound having a free amino group with a sugar having the reducing power. The pharmaceutical preparation of the present invention is capable of releasing various compounds having a free amino group in response to changes in pH and releases such compounds specifically at target parts at which the pH is lowered due to the occurrence of inflammation, tumor or the like to cause the compounds to exhibit their effects. The preparation releases the above compounds nowhere except at target parts, which is expected to result in reduction of side effects. Further, when administered in vivo, the pharmaceutical preparation of the present invention alters the in vivo behavior of the compounds as compared with that of the unmodified compounds, whereby effects such as improvement of durability in blood can be expected. It is also expected that the addition of a specific sugar enables the specific recognition of the sugar receptor, for example, galactose receptor and then the release of the sugar in response to the pH lowering in an endosome formed after the endocytosis by a cell to release a free pharmaceutical compound into the cell.

30 The present invention relates to a pharmaceutical preparation comprising a compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power.

35 There is no specific restriction as to the compounds having a free amino group to be used in the present invention. Suitable compounds include pharmaceutical compounds, for example, peptides, proteins and enzymes such as bradykinin, angiotensin, anthriopeptin, oxytocin, vasopressin, adrenocorticotropin (ACTH), calcitonin, insulin, glucagon, cholecystokinin, β

-endorphin, melanocyte-inhibiting factor, melanocyte-stimulating hormone, gastrin antagonist, neurotensin, somatostatin, brucine, cyclosporin, enkephalin, transferrin, RGD peptide, thyroid hormone, growth hormone, gonatropin, gonadotropic hormone, luteinizing hormone (LHRH), asparaginase, arginase, uricase, carboxypeptidase, glutaminase, SOD, tissue plasminogen activator (t-PA), streptokinase, interleukin, interferon, muramyl dipeptide, thymopoietin, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO), trypsin inhibitor, lysozyme, EGF, insulin-like growth factor (IGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF), endothelial cell growth factor (ECGF), fibroblast growth factor (FGF), glia cell growth factor (GGF), thymosin and specific antibodies (e.g., anti-EGF receptor antibody); carcinostatic agents such as doxorubicin derivatives [e.g., 3'-(D-Val-Leu-Lys)-doxorubisin], 5-fluorouracil derivatives [e.g., L-Ala-2-(5-fluorouracil-1-yl)-Gly], daunorubicin, idarubicin and neocarzinostatin; amino acid derivatives such as dopamine; amoxicillin, ampicillin, amantadine hydrochloride, epirubicin hydrochloride, doxorubicin hydrochloride, dopamine hydrochloride, vancomycin hydrochloride, talampicillin hydrochloride, bacampicillin hydrochloride, cycloserine, ciclacillin, cefaclor, cefatrizine, cefadroxil, cefalexin, cefaradine, cefaloxazine, tranexamic acid, norepinephrine, methyl dopa, melphalan, liothyronine sodium, astromycin sulfate, isepamicin sulfate, kanamycin sulfate, cyclonoxymycin sulfate, sisomicin sulfate, dibekacin sulfate, sulbekacin sulfate, neomycin sulfate, netilmicin sulfate, paromomycin sulfate, bleomycin sulfate, levodopa, and antibody drugs [e.g., human serum immunoglobulins (e.g., pepsin-treated human serum immunoglobulin, plasmin-treated human serum immunoglobulin, β -propiolactone-treated human serum immunoglobulin, S-alkylated human serum immunoglobulin, S-sulfonated human

serum immunoglobulin and polyethylene glycol-treated human serum immunoglobulin), mouse monoclonal antibodies, human monoclonal antibodies, chimera antibodies, anti-idiotypic antibodies and Fab fragments comprising variable region only].

5 Preferred compounds having a free amino group are peptides, proteins and enzymes such as insulin, transferrin, asparaginase, SOD, t-PA, interferon and specific antibodies, and pharmaceutical compounds such as doxorubicin hydrochloride, epirubicin hydrochloride and bleomycin sulfate.

10 In the present invention, any sugars having the reducing power can be used. Suitable sugars include glucose, lactose, fucosylglucose, galactosyllactose, fucosyllactose, lacto-N-tetraose, lacto-N-hexaose, lacto-N-neohexaose, dimannosyl-N-acetylglucosamine, sialyllactose such as
 15 3'-sialyllactose and 6'-sialyllactose, disialyllactose, N,O-diacetylneuraminylactose, 3'-sialyllactose 6'-sulfate, lactose 6'-sulfate, lactose 3'-phosphate, disialyllacto-N-tetraose and glycolipids. Also useful are compounds prepared by chemically binding a polymer (e.g.,
 20 polyoxyethylene, polyglutamic acid and polyvinylpyrrolidone) to hydroxyl groups other than the hydroxyl group formed from the reducing aldehyde group (i.e., the hydroxyl group of the hemiacetal moiety) in the above compounds. The reducing
 25 aldehyde group in the sugar chain of the sugar having the reducing power reacts with the amino group of the compound having a free amino group to give a compound in which the sugar chain is bound to the amino group moiety of the compound having a free amino group.

30 Examples of the preferred sugars are sialyllactose, lactose, glucose and disialyllactose.

Examples of the compounds which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power and which are capable of rapidly releasing the compound having a free amino group in response to changes in
 35 pH include Schiff bases and aminated compounds.

The compound having a free amino group, the sugar having

the reducing power, and the compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power may be modified with pharmaceutical carriers such as liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere or a magnetic particle. The compound having a free amino group, the sugar having the reducing power, and the compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power may also be included in the pharmaceutical carriers. The compound having an amino group to be modified with or included in the pharmaceutical carriers can be the above-mentioned pharmaceutical compounds or compounds having an amino group without any particular pharmacological activities. In addition to the compounds having a free amino group such as the above-mentioned pharmaceutical compounds, any compounds having pharmacological activities may be included in the pharmaceutical carriers.

Examples of the preferred pharmaceutical carriers are liposome, lipid emulsion and polymer micelle.

The pharmaceutical preparation of the present invention can be produced by adding 1 to 10000 parts by weight, preferably 10 to 1000 parts by weight of the sugar having the reducing power to 1 part by weight of the compound having a free amino group, which may be modified with the pharmaceutical carrier, and subjecting them to reaction by allowing them to stand in an aqueous solution of pH 7 to 14, preferably pH 7.5 to 10, at 0 to 100°C, preferably 20 to 50°C, for one minute to one month, preferably 1 to 96 hours. The pH adjustment may be carried out by using any suitable substance, for example, phosphate buffer or sodium hydroxide.

The product obtained by the above process can be used as such, as the pharmaceutical preparation of the present invention. The product may also be freeze-dried together with excipients such as mannitol, lactose or glycine according to the aimed use, storage conditions, etc. When the preparation is stored in freeze, cryoprotectants such as glycerin may be

added.

The pharmaceutical preparation of the present invention is generally used as an injection, but may also be formed into preparations for oral administration, nasal administration, 5 ophthalmic administration or percutaneous administration, a suppository, an inhalation, etc.

The pharmaceutical preparation of the present invention administered in vivo alters the in vivo behavior of the pharmaceutical compound contained therein as compared with that 10 of the unmodified compound, and thereby gives effects such as improvement of the durability of the compound in blood or specific binding of the compound to the galactose receptor in liver. When a compound having anti-tumor activity is used in the pharmaceutical preparation of the present invention, the 15 compound is released from the sugar in the neighborhood of a tumor focus due to the pH lowering around the tumor focus and thus acts directly upon tumor cells without injuring cells other than the tumor cells, whereby the production of side effects of the compound can be prevented. When an anti-EGF receptor 20 antibody is used in the pharmaceutical preparation of the present invention, the antibody modified with the sugar does not bind to the EGF receptor in normal cells, but in the neighborhood of a tumor, the sugar is released from the preparation due to the pH lowering, thus enabling the anti-EGF receptor antibody 25 to be released and to give its effect on tumor cells.

Examples and test examples of the present invention are shown below.

Best Modes for Carrying Out the Invention

30 Example 1

A solution of 0.2 mg of bovine pancreatic insulin (Wako Pure Chemical Industries, Ltd.) in 1 mL of a 2 mmol/L aqueous solution of hydrochloric acid, a solution of 320 mg of anhydrous β -lactose (Nacalai Tesque, Inc.) in 2 mL of distilled water, 35 and 1 mL of a 200 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube to give a mixture having a pH of about 8.1. The

test tube was put into a constant temperature water bath at 40°C to cause reaction. The reaction mixture was sampled after 0, 5 and 24 hours, and analyzed for products obtained by the reaction of insulin with lactose by high performance liquid chromatography (HPLC) under the following conditions.

Column: YMC-Pack ODS-A or YMC-Pack ODS-AM, 6.0 x 150 mm

Mobile phase: 100 mmol/L phosphate buffer (pH 8.0) containing 0.001% Triton X-100 : acetonitrile containing 0.001%

Triton X-100 = 25 parts by volume : 9 parts by volume

Flow rate: 1.3 mL/minute

Detection wavelength: 210 nm

As a result, it was found that three kinds of reaction products were formed by the reaction of lactose with insulin. The reaction products were designated in order of increasing retention time on HPLC as product-3, product-2, and product-1. Insulin showed the longest retention time. The results are shown in Table 1.

Table 1

Addition of Lactose to Insulin

	Insulin	Product-1	Product-2	Product-3
0 hour	100%	0%	0%	0%
5 hours	56%	35%	6%	4%
24 hours	21%	32%	11%	36%

The results in Table 1 show that lactose reacts with insulin in a weakly basic solution (pH 8.1) at 40°C with the passage of time. The proportion of product-1 was high 5 hours after the start of reaction, but after 24 hours, the proportion of product-3 increased.

Example 2

Bovine pancreatic insulin (0.2 mg, Wako Pure Chemical Industries, Ltd.) was dissolved in 1 mL of a 1 mmol/L aqueous

solution of hydrochloric acid. To about 25 mg of sialyllactose of 75% purity (a mixture of 3'-sialyllactose and 6'-sialyllactose, Boehringer Mannheim GmbH) was added 0.1 mL of a 600 mmol/L aqueous solution of disodium phosphate to make
 5 a solution. The insulin solution (0.1 mL) and the sialyllactose solution (0.1 mL) were mixed in a test tube to give a mixture having a pH of about 7.8. The test tube was put into a constant temperature water bath at 40°C to cause reaction and left for 3 days. The reaction mixture was sampled intermittently,
 10 followed by centrifugation at 3000 rpm for 20 minutes to remove insoluble materials. The samples collected 0, 1 and 3 days after the start of the reaction were analyzed for products obtained by the reaction of insulin with sialyllactose by HPLC under the following conditions.

15

Column: YMC-Pack ODS-AP, 4.6 x 150 mm

Mobile phase: 20 mmol/L phosphate buffer (pH 8.0) containing

0.001% Triton X-100 : acetonitrile containing 0.001%

Triton X-100 = 411 parts by volume : 140 parts by volume

20

Flow rate: 1.3 mL/minute

Detection wavelength: 220 nm

As a result, it was found that three kinds of reaction products were formed by the reaction of sialyllactose with
 25 insulin. The reaction products were designated in order of increasing retention time on HPLC as product-6, product-5, and product-4. Insulin showed the longest retention time. The results are shown in Table 2.

30

Table 2
Addition of Sialyllactose to Insulin

	Insulin	Product-4	Product-5	Product-6
0 hour	100%	0%	0%	0%
1 day	50%	12%	36%	2%
3 days	31%	15%	52%	3%

5 The results in Table 2 show that sialyllactose reacts with insulin in a weakly basic solution (pH 7.8) at 40°C with the passage of time. The proportion of product-5 was high as compared with the other products both after 1 day and 3 days and its proportion increased with the passage of time.

10

Example 3

15 A solution of 0.1 mg of bovine pancreatic insulin (Sigma Chemical Co.) in 0.1 mL of a 20 mmol/L aqueous solution of hydrochloric acid, a solution of 160 mg of anhydrous β -lactose (Nacalai Tesque, Inc.) in 1 mL of distilled water, and 0.9 mL of a 100 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was subjected to reaction at 37°C for 24 hours.

20 Example 4

25 Bovine pancreatic insulin (0.1 mg, Sigma Chemical Co.) was dissolved in 0.1 mL of a 20 mmol/L aqueous solution of hydrochloric acid. The solution was mixed with 0.9 mL of a 600 mmol/L aqueous solution of disodium hydrogenphosphate in a test tube to obtain a solution to be used as an insulin solution. To about 25 mg of sialyllactose of 75% purity (a mixture of 3'-sialyllactose and 6'-sialyllactose, Boehringer Mannheim GmbH) was added 0.13 mL of distilled water to make a solution. The insulin solution (0.13 mL) and the sialyllactose solution 30 (0.13 mL) were mixed in a test tube, and the mixture was subjected to reaction at 37°C for 24 hours.

Comparative Example 1

A 20 mmol/L aqueous solution of hydrochloric acid (0.1 mL), 1 mL of distilled water, and 0.9 mL of a 100 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was allowed to stand at 37°C for 24 hours.

Comparative Example 2

A solution of 0.1 mg of bovine pancreatic insulin (Sigma Chemical Co.) in 0.1 mL of a 20 mmol/L aqueous solution of hydrochloric acid, 1 mL of distilled water, and 0.9 mL of a 100 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was allowed to stand at 37°C for 24 hours.

Comparative Example 3

A solution of 160 mg of anhydrous β -lactose (Nacalai Tesque, Inc.) in 1 mL of distilled water, 0.1 mL of a 20 mmol/L aqueous solution of hydrochloric acid, and 0.9 mL of a 100 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was allowed to stand at 37°C for 24 hours to prepare solution A (lactose solution).

In a manner similar to that in Comparative Example 2, a solution of 0.1 mg of bovine pancreatic insulin (Sigma Chemical Co.) in 0.1 mL of a 20 mmol/L aqueous solution of hydrochloric acid, 1 mL of distilled water, and 0.9 mL of a 100 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was allowed to stand at 37°C for 24 hours to prepare solution B (insulin solution).

Test Example 1

A solution of 0.2 mg of bovine pancreatic insulin (Wako Pure Chemical Industries, Ltd.) in 1 mL of a 2 mmol/L aqueous solution of hydrochloric acid, a solution of 320 mg of anhydrous β -lactose (Nacalai Tesque, Inc.) in 2 mL of distilled water, and 1 mL of a 200 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was subjected to reaction at 40°C for 24 hours. To 3 mL of the resulting solution was added 0.5

mL of a 50 mmol/L aqueous solution of citric acid to adjust the pH to 6.7, and the mixture was subjected to reaction at 40°C. The samples collected from the reaction mixture 0 and 30 minutes after the start of the reaction were analyzed for products obtained by the reaction of insulin with lactose by HPLC in a manner similar to that in Example 1. The results are shown in Table 3.

Table 3

Release of Lactose Caused by pH Lowering to 6.7				
	Insulin	Product-1	Product-2	Product-3
0 minute	25%	42%	13%	20%
30 minutes	45%	18%	25%	12%

As shown in Table 3, the lowering of the pH of the mixture from 8.1 to 6.7 caused release of lactose from the products and increase in the amount of free insulin to which lactose was not bound.

Test Example 2

A solution of 0.2 mg of bovine pancreatic insulin (Wako Pure Chemical Industries, Ltd.) in 1 mL of a 2 mmol/L aqueous solution of hydrochloric acid, a solution of 320 mg of anhydrous β -lactose (Nacalai Tesque, Inc.) in 2 mL of distilled water, and 1 mL of a 200 mmol/L phosphate buffer (pH 8.4) were mixed in a test tube. The mixture was subjected to reaction at 40°C for 24 hours. To 3 mL of the resulting solution was added 0.5 mL of a 100 mmol/L aqueous solution of citric acid to adjust the pH to 5.9, and the mixture was subjected to reaction at 40°C. The reaction mixture was intermittently analyzed for products obtained by the reaction of insulin with lactose by HPLC in a manner similar to that in Example 1. The results are shown in Table 4.

Table 4
Release of Lactose Caused by pH Lowering to 5.9

	Insulin	Product-1	Product-2	Product-3
0 minute	24%	36%	13%	27%
2 minutes	35%	27%	22%	17%
10 minutes	59%	5%	33%	3%
30 minutes	76%	0%	25%	0%
60 minutes	75%	0%	25%	0%

- 5 As shown in Table 4, the lowering of the pH of the mixture from 8.1 to 5.9 caused rapid release of lactose from product-1 and product-3.

Test Example 3

- 10 A solution of 0.2 mg of bovine pancreatic insulin (Wako Pure Chemical Industries, Ltd.) in 1 mL of a 2 mmol/L aqueous solution of hydrochloric acid, a solution of 320 mg of anhydrous β -lactose (Nacalai Tesque, Inc.) in 2 mL of distilled water, and 1 mL of a 200 mmol/L phosphate buffer (pH 8.4) were mixed
- 15 in a test tube. The mixture was subjected to reaction at 40°C for 24 hours. To 3 mL of the resulting solution was added 0.5 mL of a 150 mmol/L aqueous solution of citric acid to adjust the pH to 5.0, and the mixture was subjected to reaction at
- 20 40°C. The reaction mixture was intermittently sampled and analyzed for products obtained by the reaction of insulin with lactose by HPLC in a manner similar to that in Example 1. The results are shown in Table 5.

Table 5
Release of Lactose Caused by pH Lowering to 5.0

	Insulin	Product-1	Product-2	Product-3
0 minute	21%	35%	13%	32%
2 minutes	60%	8%	27%	5%
10 minutes	83%	0%	17%	0%
30 minutes	93%	0%	7%	0%
60 minutes	95%	0%	5%	0%

- 5 As shown in Table 5, the lowering of the pH of the mixture from 8.1 to 5.0 caused rapid and almost complete release of lactose from all the products.

Test Example 4

- 10 Bovine pancreatic insulin (0.2 mg, Wako Pure Chemical Industries, Ltd.) was dissolved in 1 mL of a 1 mmol/L aqueous solution of hydrochloric acid. To about 25 mg of sialyllactose of 75% purity (a mixture of 3'-sialyllactose and
- 15 6'-sialyllactose, Boehringer Mannheim GmbH) was added 0.1 mL of a 600 mmol/L aqueous solution of disodium hydrogenphosphate to make a solution. The insulin solution (0.1 mL) and the sialyllactose solution (0.1 mL) were mixed in a test tube to give a solution having a pH of about 7.8. This solution was subjected to reaction at 40°C for 3 days and then centrifuged
- 20 at 3000 rpm for 20 minutes. To 40 μ L of the supernatant was added 0.04 mL of a 50 mmol/L aqueous solution of citric acid to adjust the pH to 6.4, and the resulting solution was subjected to reaction at 40°C. The reaction mixture was intermittently sampled and analyzed for products obtained by the reaction of
- 25 insulin with sialyllactose by HPLC in a manner similar to that in Example 2. The results are shown in Table 6.

Table 6

Release of Sialyllactose Caused by pH Lowering to 6.4

	Insulin	Product-4	Product-5	Product-6
0 minute	31%	15%	52%	3%
10 minutes	44%	9%	43%	4%
30 minutes	50%	6%	41%	3%

5 Test Example 5

Bovine pancreatic insulin (0.2 mg, Wako Pure Chemical Industries, Ltd.) was dissolved in 1 mL of a 1 mmol/L aqueous solution of hydrochloric acid. To about 25 mg of sialyllactose of 75% purity (a mixture of 3'-sialyllactose and 6'-sialyllactose, Boehringer Mannheim GmbH) was added 0.1 mL of a 600 mmol/L aqueous solution of disodium hydrogenphosphate to make a solution. The insulin solution (0.1 mL) and the sialyllactose solution (0.1 mL) were mixed in a test tube to give a solution having a pH of about 7.8. This solution was subjected to reaction at 40°C for 3 days and then centrifuged at 3000 rpm for 20 minutes. To 40 μ L of the supernatant was added 0.04 mL of a 100 mmol/L aqueous solution of citric acid to adjust the pH to 5.3, and the resulting solution was subjected to reaction at 40°C. The reaction mixture was intermittently sampled and analyzed for products obtained by the reaction of insulin with sialyllactose by HPLC in a manner similar to that in Example 2. The results are shown in Table 7.

Table 7

25 Release of Sialyllactose Caused by pH Lowering to 5.3

	Insulin	Product-4	Product-5	Product-6
0 minute	31%	15%	52%	3%
10 minutes	58%	3%	35%	4%
30 minutes	80%	5%	12%	3%

Test Example 6

Male SD strain rats were fasted for 16 to 20 hours and

then anesthetized by intraperitoneal administration of 50 mg/kg pentobarbital sodium, followed by cannulation into the femoral vein and carotid. A cannula was also inserted into the trachea to maintain airway. Five minutes before the administration of each test solution, 0.4 mL of a blood sample was collected through the cannula inserted into the carotid and transferred into a heparin-treated plastic test tube. After the blood sampling, 0.4 mL of physiological saline was put into the carotid through the cannula. The reaction mixtures obtained in Examples 3 and 4 and Comparative Examples 1 and 2 were respectively administered to the rats through the cannula inserted into the femoral vein in an amount of 20 μ L for 100 g of body weight. Solution A obtained in Comparative Example 3 was administered through the cannula inserted into the femoral vein in an amount of 20 μ L for 100 g of body weight, and immediately thereafter, solution B was intravenously administered in a similar manner. Blood samples (0.4 mL each) were collected through the cannula inserted into the carotid 5, 10, 30, 60 and 120 minutes after the administration of each test solution, and then transferred into heparin-treated plastic test tubes. After each blood sampling, 0.4 mL of physiological saline was put into the carotid through the cannula. The blood samples were centrifuged at 5°C at 10000 rpm for 5 minutes to obtain plasma. The concentration of insulin in each plasma was determined by enzyme immunoassay using GLAZYME Insulin-EIA Test (Wako Pure Chemical Industries, Ltd.) The results are shown in Table 8.

Table 8
Change in Insulin Concentration in Plasma

(unit: μ U/mL)

Time (min.)	Comp. Ex. 1	Comp. Ex. 2	Comp. Ex. 3	Ex. 3	Ex. 4
-5	23	11	13	17	7
5	31	476	506	603	589
10	42	185	186	255	242
30	22	16	13	46	56
60	34	8	4	27	23
120	24	17	15	36	20

5

As shown in Table 8, when the preparations of Examples 3 and 4 were used, the plasma insulin concentration changed in high regions as compared with the cases where the preparations of Comparative Examples 1 to 3 were used. There was no significant difference between the results obtained with the preparations of Comparative Examples 2 and 3, which indicates that the released lactose does not affect the disappearance of insulin in plasma.

15 Industrial Applicability

The present invention provides a pharmaceutical preparation which is capable of rapidly releasing a compound having a free amino group such as an amino acid derivative, a peptide, a protein or an enzyme in response to changes in pH at focuses. The preparation of the present invention is capable of improving the in vivo durability of various compounds and releasing the compounds in response to changes in pH, thus enabling the compounds to act specifically on target parts.

20

CLAIMS

1. A pharmaceutical preparation comprising a compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power and which is capable of rapidly releasing the compound having a free amino group in response to changes in pH.

2. The preparation according to claim 1, wherein said compound having a free amino group is a pharmaceutical compound.

3. The preparation according to claim 1, wherein said compound having a free amino group is selected from the group consisting of peptides, proteins, enzymes and amino acid derivatives.

4. The preparation according to claim 3, wherein said peptide is insulin.

5. The preparation according to claim 1, wherein said compound having a free amino group, sugar having the reducing power, or compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power is modified with or included in a pharmaceutical carrier.

25

6. The preparation according to claim 5, wherein said pharmaceutical carrier is selected from the group consisting of liposome, lipid emulsion, microemulsion, polymer micelle, microcapsule, microsphere and magnetic particles.

30

7. The preparation according to claim 5 or 6, wherein said compound having a free amino group is included in said pharmaceutical carrier.

35

8. The preparation according to claim 5 or 6, wherein a pharmaceutical compound is included in said pharmaceutical

ABSTRACT

The present invention provides a pharmaceutical preparation comprising a compound which can be obtained by reacting a compound having a free amino group with a sugar having the reducing power. The preparation is capable of improving the in vivo durability of various compounds and releasing the compounds in response to changes in pH, and thus is useful for causing the compounds to act specifically on target parts.

10

T02290-64769B60

DECLARATION AND POWER OF ATTORNEY FILED WITH U.S. DESIGNATED OFFICE UNDER 35 U.S.C. 371(c)(4)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL PREPARATIONS

the specification of which was filed as PCT International Application No. PCT/JP99/07278
 filed 24 December 1999 and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
PCT/JP98/05857	PCT	24/12/98	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
H09-177022	Japan	02/07/97	<input type="checkbox"/>	<input checked="" type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status: patented, pending, abandoned)

I hereby appoint as principal attorneys; Donald R. Antonelli, Reg. No. 20,296; David T. Terry, Reg. No. 20,178; Melvin Kraus, Reg. No. 22,466; Stanley A. Wal, Reg. No. 26,432; William I. Solomon, Reg. No. 28,565; Gregory E. Montone, Reg. No. 28,141; Ronald J. Shore, Reg. No. 28,577; Donald E. Stout, Reg. No. 26,422; Alan E. Schiaveli, Reg. No. 32,087; James N. Dresser, Reg. No. 22,973 and Carl I. Brundidge, Reg. No. 29,621 to prosecute and transact all business connected with this application and any related United States application and international applications. Please direct all communications to the following address:

Antonelli, Terry, Stout & Kraus, LLP
Suite 1800
1300 North Seventeenth Street
Arlington, Virginia 22209
Telephone: (703)312-6600
Fax: (703)312-6666

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date 15 June 2001 Inventor 1-00 Yasuki Kato
Inventor's Signature [Signature]
Residence Susono-shi, Japan Citizenship Japan
Post Office Address c/o Pharmaceutical Research Institute, KYOWA HAKKO KOGYO
CO., LTD., 1188, Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731
Japan

Date 15 June 2001 Inventor 2-0 Hiroko Kusano
Inventor's Signature [Signature]
Residence Sunto-gun, Japan Citizenship Japan
Post Office Address c/o Pharmaceutical Research Institute, KYOWA HAKKO KOGYO
CO., LTD., 1188, Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731
Japan

Date 15 June 2001 Inventor 3-0 Yuji Kawaguchi
Inventor's Signature [Signature]
Residence Tagata-gun, Japan Citizenship Japan
Post Office Address c/o Pharmaceutical Research Institute, KYOWA HAKKO KOGYO
CO., LTD., 1188, Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731
Japan

Date 18 June 2001 Inventor 4-0 Kunio Ito
Inventor's Signature [Signature]
Residence Same as Post Office Address Citizenship Japan
Post Office Address 174-13, Nameri, Nagaizumi-cho, Sunto-gun, Shizuoka
411-0933 Japan